title: Modulation of cardiac autonomic control in humans by angiotensin II.
abstract: Angiotensin II (Ang II) exerts an inhibitory action on vagal activity in animals and may also facilitate sympathetic activity. The object of this study was to compare autonomic activity resulting from equivalent steady-state baroreflex activation during intravenous Ang II infusion with that resulting from a control infusion of phenylephrine. Eight healthy subjects aged 22 to 34 years were studied in a single-blind, randomized, prospective crossover study. Autonomic activity was determined by computer analysis of RR interval variability in the time and frequency domains. Despite equal experimental hypertension with Ang II and phenylephrine infusion, at peak infusion rates the mean RR interval was significantly shorter with Ang II (983 +/- 179 milliseconds; mean +/- SD) than with phenylephrine (1265 +/- 187 milliseconds, P < .01). The variability of RR intervals was not significantly different, but the variability (median interquartile difference) of RR interval successive differences was significantly lower with Ang II (66 milliseconds) than with phenylephrine (104 milliseconds, P < .02). Power spectral analysis revealed the power of the 0.25-Hz component in normalized units to be significantly smaller during Ang II infusion (20.5 +/- 12.7 U) than during phenylephrine (38.2 +/- 14.7 U, P < .05), whereas the power of the 0.1-Hz component was significantly greater during Ang II infusion (67.8 +/- 17.1 U) than phenylephrine (38.8 +/- 20.3 U, P < .05). Measures of vagal modulation of heart rate were significantly attenuated, and sympathetic modulation appeared to be increased during Ang II infusion compared with control phenylephrine infusions. These observations may underlie reports of increased vagal activity during angiotensin-converting enzyme inhibitor therapy.
authors.affiliation: University of Birmingham Department of Cardiovascular Medicine, Queen Elizabeth Hospital, Edgbaston, UK.
authors.forename: J N
authors.initials: JN
authors.lastname: Townend
authors.forename: M
authors.initials: M
authors.lastname: al-Ani
authors.forename: J N
authors.initials: JN
authors.lastname: West
authors.forename: W A
authors.initials: WA
authors.lastname: Littler
authors.forename: J H
authors.initials: JH
authors.lastname: Coote
mesh_terms: D000328:Adult; D000804:Angiotensin II / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects*; D018592:Cross-Over Studies; D006321:Heart / Q000294:innervation*; D006801:Humans; D008297:Male; D010656:Phenylephrine / Q000494:pharmacology; D011446:Prospective Studies; D012815:Signal Processing, Computer-Assisted; D016037:Single-Blind Method
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II; D010656:Phenylephrine